Prof. Carvallo, Argentina : "Regions that use ivermectin are doing much better !"
In this Debriefing interview, Professor Hector Carvallo, a specialist in infectious disease medicine in Argentina, offers a unique insight into the effective treatment of COVID-19 with the anti-parasitic drug ivermectin. Professor Carvallo is a physician and clinical researcher, who had been studying several important uses of ivermectin to treat viral and parasitic diseases prior to the COVID-19 pandemic. He is now recognised worldwide as a pioneer in the use of the drug to treat COVID-19 patients.
Prof. Carvallo is the Lead Investigator in the IDEA and IVERCAR clinical trials: two pioneering studies on the use of ivermectin for the prevention and treatment of COVID-19. He has also done ground breaking research into the combined use of ivermectin, iota-carrageenan and bromhexine as both prophylaxis and treatment for COVID-19.
In this Debriefing interview, offered in partnership with the French civic group www.BonSens.org, Professor Carvallo gives details of the effects of ivermectin on the pandemic in Argentina, which is widely used in a number of provinces. He compares the experience of those provinces using ivermectin with other provinces that chose not to use the drug. He also discusses the recent decision of the European Medicines Agency not to recommend the use of ivermectin to treat COVID-19 patients… and he does not pull his punches...
Original version (english) :
French version (dubbed by Jeanne)
À LIRE AUSSI
L'article vous a plu ? Il a mobilisé notre rédaction qui ne vit que de vos dons.
L'information a un coût, d'autant plus que la concurrence des rédactions subventionnées impose un surcroît de rigueur et de professionnalisme.
Avec votre soutien, France-Soir continuera à proposer ses articles gratuitement car nous pensons que tout le monde doit avoir accès à une information libre et indépendante pour se forger sa propre opinion.
Vous êtes la condition sine qua non à notre existence, soutenez-nous pour que France-Soir demeure le média français qui fait s’exprimer les plus légitimes.
Si vous le pouvez, soutenez-nous mensuellement, à partir de seulement 1€. Votre impact en faveur d’une presse libre n’en sera que plus fort. Merci.